Castillo MDA, Carrera MP, Muñoz OS, Chacón JPA, García CAM, Fierro LJD, Castillo SDE

Language: Spanish
References: 12
Page: 81-84
PDF size: 259.70 Kb.

ABSTRACT

Human papillomavirus beta (HPVβ) has recently been associated with non-melanoma skin cancer (NMSC), although a specific role in its pathogenesis has not been clarified. During the past few years, two theories have been proposed. The first one, suggesting the HPVβ could be involved in the early stages of ultravioletinduced NMSC pathogenesis and the second one, attributing a protective role.
There is anecdotal evidence of HPV vaccines administration, which are made against human papillomavirus alpha (HPVα), resulting in clinical regression of the squamous cell carcinoma (SCC). A possible explanation for these findings is that HPVα can be found in SCC lesions along with HPVβ generating a crossreactivity. It is also thought that the virus-like particles used in the vaccines stimulate innate immunity.
Hence, the hpvα vaccine, could be used as treatment of nmsc within patients who are not candidates to surgical management or other treatment alternatives as it has been reported by Nichols et al. in various case reports, as well as our own experience in a dermatologic and rheumatologic institute.

REFERENCES

1. Doorbar J, Egawa N, Griffin H, Kranjec C y Murakami I, Human papillomavirus molecular biology and disease association, Rev Med Virol 2015; 25(S1):2-23.

2. Quint KD, Genders RE, De Koning MN, Borgogna C, Gariglio M, Bavinck JNB et al., Human beta-papillomavirus infection and keratinocyte carcinomas, J Pathol 2015; 235(2):342-54.

3. Tampa M, Mitran C, Mitran M, Nicolae I, Dumitru A, Matei C et al., The role of beta hpv types and hpv-associated inflammatory processes in cutaneous squamous cell carcinoma, Journal of Immunology Research 2020.

4. Venuti A, Lohse S, Tommasino M y Smola S, Cross-talk of cutaneous beta human papillomaviruses and the immune system: determinants of disease penetrance, Philosophical Transactions of the Royal Society B 2019; 374.

5. Ao C y Zeng K, The role of regulatory t cells in pathogenesis and therapy of human papillomavirus-related diseases, especially in cancer, Infection, Genetics and Evolution 2018; 65(1):406-13.

6. Hochheiser K, Gyorki DE y Gebhardt T, Skin colonization with beta papillomavirus drives tissue immunity and resistance to squamous cell cancer, Immunology & Cell Biology 2020; 98:9-11.

7. Pham C, Juhasz M, Sung C y Atanaskova Mesinkovska N, The human papillomavirus vaccine as a treatment for human papillomavirus related dysplastic and neoplastic conditions: a literature review, Journal of the American Academy of Dermatology 2020; 82(1):202-12.

8. Mohsen M, Speiser D, Knuth A y Bachmann M, Virus-like particles for vaccination against cancer, wires Nanomed Nanobiotechnol 2020; 12:e1579. Figura 3. Evolución del tratamiento en un paciente con carcinoma escamocelular.

9. Guptaa R, Radyb P, Doanc H y Tyringb S, Development of a β-hpv vaccine: updates on an emerging frontier of skin cancer prevention, Journal of Clinical Virology 2020; 126:104348.

10. Nichols A, De Bedout V, Fayne R, Burke G, Kirsner R e Ioannides T, Systemic and intratumoral 9-valent human papillomavirus vaccine treatment for squamous cell carcinoma in situ in a renal transplant recipient, jaad Case Reports 2020; 6(4):289-91.

11. Nichols A, Allen A, Shareef S, Badiavas E, Kirsner R e Ioannides T, Association of human papillomavirus vaccine with the development of keratinocyte carcinomas, jama Dermatology 2017; 153(6):571.

12. Nichols A, González A, Clark E, Khan W, Rosen A, Guzmán W et al., Combined systemic and intratumoral administration of human papillomavirus vaccine to treat multiple cutaneous basaloid squamous cell carcinomas, jama Dermatology 2018; 154(8):927.